The three overlapping phases of normal wound repair — inflammation, proliferation, remodeling — and how exogenous growth factor delivery can support a stalled healing cascade
Wound healing begins the instant tissue is injured. Vasoconstriction and platelet aggregation form a fibrin clot within minutes, achieving hemostasis and providing a provisional matrix. Chemotactic signals released from degranulating platelets and damaged cells then recruit neutrophils (within hours) and monocyte-derived macrophages (by day 2–3), which phagocytose debris, bacteria, and dead tissue while releasing cytokines that orchestrate the transition into proliferation.
Hemostasis (minutes): • Vasoconstriction limits blood loss; platelets adhere to exposed collagen and aggregate • Platelet degranulation releases PDGF, TGF-β, and other chemotactic factors • Fibrinogen converts to fibrin, forming a provisional clot/matrix that also serves as a scaffold for incoming cells
Neutrophil recruitment (hours 1–48): • Chemoattracted by complement fragments, bacterial products, and platelet signals • Phagocytose bacteria and debris; release reactive oxygen species and proteases • Undergo apoptosis and are cleared as the phase resolves — persistence signals a problem
Macrophage transition (day 2–3 onward): • Monocytes infiltrate and differentiate into macrophages • Continue debridement of remaining debris and spent neutrophils • Shift phenotype from pro-inflammatory (M1-like) toward a reparative, pro-angiogenic profile (M2-like), releasing PDGF, VEGF, and TGF-β that recruit fibroblasts and endothelial cells • This macrophage phenotype switch is widely regarded as the functional bridge into the proliferative phase
The inflammatory phase is protective, not destructive — its cytokine output is what recruits the fibroblasts and endothelial cells needed for the next phase. Problems arise only when inflammation fails to resolve on schedule, which is the central concern addressed later in the impaired-healing topic.
As inflammation resolves, the wound bed shifts to tissue-building mode. Endothelial cells sprout new capillaries toward the hypoxic wound center (angiogenesis), fibroblasts migrate in and proliferate, and myofibroblasts begin contracting the wound margins. Fibroblasts synthesize a collagen-rich extracellular matrix that, together with the new capillary network, forms granulation tissue — the pink, vascular tissue that fills the defect before re-epithelialization can seal the surface.
Angiogenesis: • Hypoxia and macrophage-derived VEGF/FGF drive endothelial sprouting from adjacent intact vessels • New capillary loops give granulation tissue its characteristic vascular, granular appearance • Adequate perfusion is required to sustain the metabolically active cells filling the wound
Fibroblast recruitment and matrix deposition: • Fibroblasts migrate along the fibrin scaffold, proliferate, and begin synthesizing extracellular matrix • Early matrix is dominated by type III collagen, glycosaminoglycans, and fibronectin — looser and more disorganized than mature tissue • A subset of fibroblasts differentiate into myofibroblasts, which express contractile actin and pull wound margins inward
Re-epithelialization (parallel process): • Keratinocytes at the wound edge migrate across the granulation tissue surface • Epithelial migration and matrix deposition proceed together — a wound bed with healthy granulation tissue supports faster surface coverage
Granulation tissue is intentionally provisional — it is disorganized, highly cellular, and mechanically weak by design, trading structural strength for the speed needed to close the defect. Its architecture is completely overhauled in the remodeling phase that follows.
Remodeling is the longest phase of wound healing, unfolding over weeks to as long as one to two years. Type III collagen laid down during proliferation is progressively degraded by matrix metalloproteinases and replaced with stronger, more organized type I collagen, which cross-links and aligns along lines of mechanical tension. Cellularity and vascularity gradually decrease as the tissue matures from vascular granulation tissue into a paler, less cellular scar.
Collagen turnover: • Matrix metalloproteinases (MMPs) degrade the disorganized type III collagen matrix • Fibroblasts synthesize type I collagen, which is stronger and more highly cross-linked • The balance between MMPs and their tissue inhibitors (TIMPs) determines net matrix remodeling
Fiber reorganization: • Collagen fibers, initially deposited in a random meshwork, progressively reorient along the wound's dominant lines of mechanical tension • This alignment — not an increase in total collagen — is the primary driver of rising tensile strength
Regression of cells and vessels: • Many myofibroblasts and endothelial cells undergo apoptosis as demand for contraction and perfusion falls • The tissue becomes progressively less cellular and less vascular, and the scar pales as capillary density falls
Tensile strength ceiling: • Even a fully remodeled scar typically recovers only roughly 70–80% of the tensile strength of uninjured skin • Strength gain is gradual and continues long after the wound surface appears closed
Remodeling explains why a “closed” wound is not a “healed” wound in the mechanical sense — visible closure of the surface can occur well before the underlying collagen architecture has reorganized enough to approach its eventual strength ceiling.
Growth factor delivery is a therapeutic strategy that supplies exogenous signaling proteins — such as PDGF, VEGF, EGF, FGF, or TGF-β — directly to a wound, either topically or through engineered delivery systems, to reinforce steps of the endogenous cascade. Rather than replacing the biology of the three healing phases, delivered growth factors aim to amplify recruitment, proliferation, and matrix synthesis at the point in the cascade where endogenous signaling is insufficient.
Mechanistic rationale: • Growth factors act by binding cell-surface receptors on neutrophils, macrophages, fibroblasts, and endothelial cells, triggering intracellular signaling that drives migration, proliferation, or matrix synthesis • Delivering them exogenously provides an additional pool of signal on top of whatever the wound is producing endogenously
Delivery approaches: • Topical formulations apply growth factor directly to the wound surface • Engineered delivery systems (hydrogels, scaffolds, sustained-release dressings) aim to keep growth factor concentrated at the wound site and active for longer than a single topical application • Delivery system design is a major determinant of how much benefit a given growth factor can provide, since these proteins are otherwise degraded quickly in a wound environment
Where the strategy is most relevant: • Growth factor therapy is considered particularly valuable in wounds where endogenous growth factor signaling is impaired — the wound is present but the natural cascade is not progressing on its own • In wounds already progressing through the phases on a normal timeline, exogenous growth factor support is a smaller marginal contributor
Growth factor delivery is best understood as reinforcing a specific, often deficient, step of a cascade that is otherwise biologically intact — it supports progression through the same inflammatory–proliferative–remodeling sequence rather than substituting for it.
Not every wound proceeds smoothly through inflammation, proliferation, and remodeling. Certain local factors (poor perfusion, infection, repeated trauma, persistent biofilm) and systemic conditions (diabetes, malnutrition, immunosuppression) can interrupt normal progression, most often trapping the wound in a prolonged inflammatory state rather than allowing it to advance. Interventions — including growth factor therapy — aim to help these stalled wounds re-enter a productive trajectory toward proliferation and remodeling.
Why the inflammatory phase can persist: • Ongoing bacterial burden or biofilm continuously re-triggers neutrophil recruitment • Poor tissue perfusion limits oxygen and nutrient delivery needed for the metabolically demanding proliferative phase • Systemic conditions such as diabetes are associated with altered macrophage phenotype switching, so the reparative, pro-angiogenic signaling needed to transition out of inflammation is diminished • Repeated mechanical trauma or pressure can re-injure fragile new tissue before it has a chance to mature
Consequences of a stalled cascade: • The wound bed remains inflamed rather than transitioning to granulation tissue • Endogenous growth factor signaling — the same signaling that growth factor therapy aims to reinforce — is itself often diminished in this state, which is part of why exogenous delivery is considered
How intervention aims to help: • Addressing the underlying driver (debridement, infection control, perfusion optimization) removes the trigger keeping the wound in prolonged inflammation • Growth factor delivery is positioned to help resupply the pro-proliferative signals a stalled wound is not generating adequately on its own, supporting re-entry into the proliferative phase • None of these interventions bypass the underlying phase biology — the goal is always to help the wound resume a normal progression through inflammation, proliferation, and remodeling
The framing of “stalled vs. on trajectory” used in this simulator is illustrative — real chronic wounds are assessed clinically over time using wound-bed appearance, size trends, and patient-specific risk factors, not a single day-count threshold.